News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioInvent Release: Recruitment of Patients Completed in Phase II Study with BI-204


3/2/2012 6:31:03 AM

LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (OMXS: BINV) and its collaborator Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that all patients have completed enrollment in the GLACIER study, a phase IIa study with BI-204 in patients with stable atherosclerotic vascular disease. BioInvent expects to publicly release top-line data from the study in Q3 2012.

Read at BioSpace.com

comments powered by Disqus
BioInvent
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES